RU-2025137519-A - CLL1 CAR T-CELL, METHOD OF ITS PRODUCTION AND ITS APPLICATION

Inventors

• ЯН, Синь
• ЧЖУ, Цзяньгао
• ЯН, Вэньцзюнь
• ЮЙ, Цзяньдун

Assignees

• КАРБИОДЖЕН ТЕРАПЬЮТИКС КО., ЛТД.

Dates

Publication Date

20260508

Application Date

20240104

Priority Date

20230609

Claims (20)

1. 1. A CLL1 CAR T cell comprising a chimeric antigen receptor, wherein said chimeric antigen receptor comprises a single-domain antibody, a hinge region, a transmembrane region and an intracellular signaling region, and the amino acid sequence of the single-domain antibody corresponds to positions 22-150 in SEQ ID NO: 1.
2. 2. The CLL1 CAR T cell of claim 1, wherein the intracellular signaling region comprises a 4-1BB costimulatory domain and a CD3ζ activation domain, the amino acid sequence of 4-1BB corresponds to positions 220-266 in SEQ ID NO: 1, and the amino acid sequence of CD3ζ corresponds to positions 267-378 in SEQ ID NO: 1.
3. 3. The CLL1 CAR T cell of claim 1 or 2, wherein the hinge region is a CD8a hinge region with an amino acid sequence corresponding to positions 151-195 in SEQ ID NO: 1, and the transmembrane region is a CD8a transmembrane region with an amino acid sequence corresponding to positions 196-219 in SEQ ID NO: 1.
4. 4. The CLL1 CAR T cell according to any one of paragraphs 1-3, characterized in that the chimeric antigen receptor comprises any of the following:
5. A1) a protein with the amino acid sequence presented in SEQ ID NO: 1 or positions 22-378 in SEQ ID NO: 1;
6. A2) a protein obtained by substitution and/or deletion and/or addition of amino acid residues in the amino acid sequence presented in SEQ ID NO: 1 or positions 22-378 in SEQ ID NO: 1, which is characterized by more than 80% identity with the protein in A1) and the same function;
7. A3) a fusion protein obtained by linking a tag or signal peptide to the N-terminus and/or C-terminus of A1) or A2), with the same function as A1).
8. 5. A chimeric antigen receptor as defined in any one of paragraphs 1-4.
9. 6. Biological material that is any of the following:
10. B1) a nucleic acid molecule encoding a chimeric antigen receptor according to paragraph 5;
11. B2) an expression cassette containing a nucleic acid molecule from B1);
12. B3) a recombinant vector containing a nucleic acid molecule from B1), or a recombinant vector containing an expression cassette from B2);
13. B4) a recombinant microorganism containing a nucleic acid molecule from B1), or a recombinant microorganism containing an expression cassette from B2), or a recombinant microorganism containing a recombinant vector from B3).
14. 7. The biological material according to paragraph 6, characterized in that the nucleic acid molecule from B1) is any of the following:
15. C1) a DNA molecule with a nucleotide sequence or coding sequence presented at positions 64-1134 in SEQ ID NO: 2;
16. C2) a DNA molecule with more than 75% identity to the nucleotide sequence defined in C1) and with the same function;
17. C3) a DNA molecule with a nucleotide sequence or coding sequence presented in SEQ ID NO: 2;
18. C4) a DNA molecule with more than 75% identity to the nucleotide sequence from C3) and with the same function.
19. 8. A pharmaceutical composition comprising a CLL1 CAR T cell according to any one of claims 1 to 4.
20. 9. Any of the following uses of a CLL1 CAR T cell according to any one of claims 1-4, a chimeric antigen receptor according to claim 5, a biological material according to claim 6 or 7, or a pharmaceutical composition according to claim 8: